Thrombus Articles & Analysis
15 news found
” An estimated 435,000 PE events occur each year in the six largest European Union (EU) countries.1 Compared to the United States, the prevalence of PE is higher for those patients admitted to the emergency department in Europe, and European patients also had higher acuity and worse outcomes.2 The CE Mark for the AlphaVac F1885 System expands treatment options for healthcare professionals ...
PE represents the third-leading cause of cardiovascular mortality in the United States.1 “The completion of the APEX-AV Study to assess the performance of the AlphaVac F1885 System in reducing thrombus burden and improving right ventricular function is a meaningful step toward expanding treatment options and improving care for patients with pulmonary embolism,” said ...
FXIa inhibition specifically targets the FXIa protein involved in pathological thrombus formation, but leaves the pathway involved in the physiological healing of vessel wall injuries intact. ...
ByBayer AG
Over 90% met the primary endpoint of complete or near-complete thrombus extraction and there was only one device-related serious adverse event. ...
These data suggest that safe, rapid thrombus extraction with FlowTriever may significantly improve the natural course of the ...
The study evaluates the safety and effectiveness of the ClotTriever system including thrombus removal, hospital resource utilization, and long-term clinical results. ...
Factor XI is a promising and differentiated target for the development of safer anticoagulants because of its critical role in pathological versus normal thrombus formation uncoupling hemostasis from thrombosis. Patients with congenital Factor XI genetic deficiency demonstrate a lower risk for venous thromboembolism and ischemic stroke but rarely have spontaneous bleeding.1 The ...
ByBayer AG
TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices. ...
ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of ...
Echocardiographic and CT analysis reported normal leaflet mobility, no leaflet calcification or thrombus generation. Echocardiographic and CT imaging data showed consistent laminar flow throughout the valve and long coaptation length in all five patients. ...
CVI can manifest in multiple ways, the most severe forms resulting in skin changes and ulcers, leading to poor quality of life for patients as well as life threatening complications like acute deep vein thrombus formation.2 “The rapid enrollment of the VIVID Trial is a testimonial to the magnitude and severity of chronic venous insufficiency and the dedication of our ...
“The financing will accelerate Truvic’s development programs and preparations to enter the rapidly-growing market for peripheral thrombus management.” D1 Capital Partners, founded in 2018, is a global investment firm that invests in both public and private markets. ...
The ALTO device was specifically chosen for this patient because he felt the patient’s short, thrombus-lined conical aortic neck could only be treated using ALTO. “We are very excited to have access to the ALTO device given its unique approach to excluding the aneurysm using a custom sealing technology, and the higher sealing ring enabled me to land and seal in ...
We are particularly excited about the excellent outcomes we saw during long-duration studies where we noted minimal hemolysis and only minor clinically insignificant thrombus formation after over 40 hours of operation.” Richardson further stated, “These studies, again, give evidence to the advantages of the unique design for our catheter-based product. ...
Successful revascularization and blood flow restoration is essential in the treatment and quality of life improvement for this patient population The Rex Medical Revolution™ Peripheral Atherectomy System is an innovative and ergonomically designed low profile rotational atherectomy system (140,000 RPM) with continuous mechanical aspiration for below-the-knee (BTK) and above-the-knee ...